Search
Solutions

Organoid Service

º Oncology

Patient-derived cancer organoid based drug evaluation service

The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs).

This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation with Patient-Derived Organoids (PDOs)

High-Fidelity Preclinical Models

Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.

These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.

Extensive Organoid Biobanking

A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.

This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.

Established Cancer Organoid
Available pre-clinical research
  • Donor-matched immune microenvironment
  • Various patient-derived organoid lineups
  • High-resolution data (HCS, FACS, NGS, scRNAseq, multiflex IHC)
  • Fully customized service
PSC-derived organoid
  • Basic clinical data
  • Drug sensitivity prediction
  • Patient follow-up data
  • Clinical bioinformatics (NGS, RNAseq, Spatial biology)

Enhance clinical predictive accuracy by developing advanced in vitro models that more accurately recapitulate the Tumor Microenvironment (TME)

Immune-Microenvironment with Cytotoxic T cells
Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding
Establishment of an immune checkpoint blockade evaluation platform utilizing cancer organoids and autologous T cells
Professor Lee Chang-seok Eulji University
Customer insight

Advancing K-Beauty with Skin Organoids: A Next-Generation Platform for Non-Animal Testing and High-Precision Cosmetic Innovation

With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...

Tomocube (Spatial)
Customer insight

HT-X1: A Label-Free Imaging Breakthrough for Organoid-Based Disease Modeling and Drug Screening

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...

Seoul National University College of Medicine
Customer insight

Pioneering Spatial Protein Analysis in Korea: Advancing Clinical Pathology with Lambda Biologics’ Support

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...

K Research Institute
Customer insight

ODISEI-Gut Platform Reveals Immune-Boosting Potential of Kimchi-Derived Bacterial Strain

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells...

Bundang Jesaeng General Hospital
Customer insight

Multiplex Marker Analysis Enhances Research Efficiency with 31-Marker Detection on a Single Slide

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...

Cancer Organoid

Endometrial Cancer Organoid

Cancer Organoid

Endometrial Cancer Organoid

1784€+

Hepatocellular Carcinoma Organoid

Cancer Organoid

Hepatocellular Carcinoma Organoid

1784€+

Lung Cancer Organoid

Cancer Organoid

Lung Cancer Organoid

1784€+

Ovarian Cancer Organoid

Cancer Organoid

Ovarian Cancer Organoid

1784€+

Gastric Cancer Organoid

Cancer Organoid

Gastric Cancer Organoid

1784€+

Pancreatic Cancer Organoid

Cancer Organoid

Pancreatic Cancer Organoid

1784€+

Colorectal Cancer Organoid

Cancer Organoid

Colorectal Cancer Organoid

1784€+

Cholangiocarcinoma Organoid

Cancer Organoid

Cholangiocarcinoma Organoid

1784€+

Breast Cancer Organoid

Cancer Organoid

Breast Cancer Organoid

1784€+

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

Cytotoxic T cell

Tumor Microenvironment

Cytotoxic T cell

6003€+

Tumor-Infiltrating Lymphocyte

Tumor Microenvironment

Tumor-Infiltrating Lymphocyte

9057€+

Regulatory T cell

Tumor Microenvironment

Regulatory T cell

7500€+

Macrophage

Tumor Microenvironment

Macrophage

7500€+

Validation Complete for cancer organoid

  • Clinical information
  • Drug sensitivity test
  • Genetic mutation (WES analysis)
  • Specific cancer marker expression (Immunohistochemistry, Multiflex)
WES analysis in pancreatic cancer organoid
Drug sensitivity test in pancreatic cancer organoid

Connect with Us